Apr 19, 2006:
iCo Therapeutics to Present at Major Biotechnology Conference |
| Read More > |
 |
Mar 2, 2006:
World-Renowned Retinal Specialist joins iCo Therapeutics’ Strategic Advisory Team
iCo Therapeutics Inc. announced today that Dr. Alan Bird has joined iCo’s Strategic Advisory Team. |
| Read More > |
|
Feb 15, 2006:
iCo Therapeutics Selects Isis Pharmaceuticals to Manufacture and Supply iCo 007
iCo Therapeutics Inc. announced today that it has selected Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) to manufacture and supply iCo 007. |
| Read More > |
|
Feb 8, 2006:
Pace of iCo unmatched by biotech competitors
Pace of iCo unmatched by biotech competitors |
| Read More > |
|
Nov 30, 2005:
iCo Therapeutics Announces Strategic Advisory Team
iCo Therapeutics Announces Strategic Advisory Team Dr. Julia Levy, Dr. George Lasezkay, Richard Glickman to provide strategic input to the Vancouver biotech firm |
| Read More > |
|
Nov 15, 2005:
iCo Therapeutics to Present at BioFinance Early Phase 2005 on November 16th, 2005 |
| Read More > |
|
Nov 8, 2005:
iCo Therapeutics named one of Canada’s top investment prospects by the Ottawa Life Sciences Council |
| Read More > |
|
Oct 17, 2005:
iCo Therapeutics to Present at BIO InvestorForum in San Francisco on October 20, 2005
To view a webcast of Mr. Rae’s presentation, click here |
| Read More > |
|
Sep 29, 2005:
iCo Therapeutics to Present at BioContact
iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at the BioContact Quebec Biopharmaceutical Partnership Symposium to be held October 5-7th, 2005 in Quebec City, Quebec. |
| Read More > |
|
Aug 25, 2005:
Isis Pharmaceuticals Licenses Antisense Drug to iCo Therapeutics for the Treatment of Eye Diseases
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and iCo Therapeutics Inc. announced today that Isis has granted an exclusive worldwide license to iCo for the development and commercialization of ISIS 13650, a second-generation antisense drug. |
| Read More > |
|
Jul 19, 2005:
iCo Therapeutics Appoints Internationally Recognized Expert in Immunology and Ophthalmology as Chief Scientific Officer
iCo Therapeutics Inc. announced today the appointment of Professor Santa Jeremy Ono, a leading authority in the fields of immunology and ophthalmology, as Chief Scientific Officer. |
| Read More > |
